您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > NESS 0327
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
NESS 0327
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
NESS 0327图片
CAS NO:494844-07-4
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
NESS 0327 是一种大麻素拮抗剂,对大麻素 CB1 受体具有高选择性。
Cas No.494844-07-4
化学名8-chloro-1-(2,4-dichlorophenyl)-1,4,5,6-tetrahydro-N-1-piperidinyl-benzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide
Canonical SMILESClc1ccc2c(CCCc3c(nn(c23)c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1
分子式C24H23Cl3N4O
分子量489.8
溶解度≤0.25mg/ml in ethanol;0.25mg/ml in DMSO;0.5mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Ki: 0.35 pM and 21 nM for CB1 and CB2 receptor, respectively.

NESS 0327 is an extremely potent cannabinoid (CB) receptor antagonist.

Cannabinoid CB1 receptors are present in the central nervous system with the highest densities in the hippocampus, and to a lesser extent in some peripheral tissues. Cannabinoid CB2 receptors are predominantly located in peripheral tissues. Both receptors can negatively regulate adenylate cyclase and control the release of arachidonic acid.

In vitro: Previous study found that NESS 0327 exhibited a stronger selectivity for CB1 receptor compared with SR 141716A, showing a much higher affinity for CB1 receptor and a higher affinity for the CB2 receptor. Affinity ratios demonstrated that NESS 0327 was more than 60,000-fold selective for the CB1 receptor. NESS 0327 alone did not produce concentration-dependent stimulation of guanosine 5'-O-(3-[35S]thio)-triphosphate binding in rat cerebella membranes. Conversely, NESS 0327 antagonized WIN 55,212-2-stimulated guanosine 5'-O-(3-[35S]thio)-triphosphate binding. In functional assay, NESS 0327 could antagonize the inhibitory effects of WIN 55,212-2 on electrically evoked contractions in mouse isolated vas deferens preparations [1].

In vivo: In vivo studies showed that NESS 0327 could antagonize the antinociceptive effect produced by WIN 55,212-2 in both tail-flick and hot-plate test, suggesting that NESS 0327 was a novel cannabinoid antagonist with high selectivity for the cannabinoid CB1 receptor [1].

Clinical trial: So far, no clinical study has been conducted.

Reference:
[1] Ruiu, S. ,Pinna, G.A.,Marchese, G., et al. Synthesis and characterization of NESS 0327: A novel putative antagonist of the CB1 cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics 306(1), 363-370 (2003).